• Explore /
  • Poster
  • / Phase II basket trial evaluating the efficacy of pembrolizumab (PE) combined with vorinostat (VO) in patients (pts) with recurrent and/or metastatic squamous cell carcinoma (SCC).

Phase II basket trial evaluating the efficacy of pembrolizumab (PE) combined with vorinostat (VO) in patients (pts) with recurrent and/or metastatic squamous cell carcinoma (SCC).

Abstract Poster

Authors

null

Christophe Le Tourneau

Curie Institute, Paris, France

Christophe Le Tourneau , Frédéric Bigot , Damien Vansteene , Maud Kamal , François Ghiringhelli , Luca Mazzarella , Christian Borel , Raphael Chaltiel , Benoit You , Carlos A. Gomez-Roca , Sophie Cousin , Elodie Coquan , Aurélien Lambert , Esma Saada-Bouzid , Xavier Durando , François Legrand , Amellie Lusque , Fabrice Andre , Thomas Filleron

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Immunotherapy

Track

Developmental Therapeutics—Immunotherapy

Sub Track

PD1/PD-L1 Inhibitor Combinations

Clinical Trial Registration Number

NCT04357873

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 2597)

DOI

10.1200/JCO.2023.41.16_suppl.2597

Abstract #

2597

Poster Bd #

439

Abstract Disclosures

Similar Posters

First Author: Jianqing Zhu

First Author: Andreas Nicholas Saltos

First Author: Deborah J.L. Wong

Poster

2020 ASCO Virtual Scientific Program

Phase II randomized trial of first-line pembrolizumab and vorinostat in patients with metastatic NSCLC (mNSCLC).

Phase II randomized trial of first-line pembrolizumab and vorinostat in patients with metastatic NSCLC (mNSCLC).

First Author: Andreas Nicholas Saltos